D3-binding molecules and uses thereof
US-2024376194-A1 · Nov 14, 2024 · US
Monoclonal and oligoclonal anti-egfr antibodies for use in the treatment of tumors expressing predominantly high affinity egfr ligands or tumors expressing predominantly low affinity egfr ligands
US2016083800A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016083800-A1 |
| Application number | US-201514833834-A |
| Country | US |
| Kind code | A1 |
| Filing date | Aug 24, 2015 |
| Priority date | Jun 3, 2011 |
| Publication date | Mar 24, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed are pharmaceutical preparations for, and methods for determining, appropriate and effective treatment with therapeutic agents comprising a single species of anti-EGFR monoclonal antibody or therapeutic agents comprising a plurality of species of such antibodies, as well as kits useful for making such determinations.
First claim
Opening claim text (preview).
What is claimed is: 1 . A method for determining whether or not matuzumab should be used to treat a malignant tumor, the method comprising: obtaining a biopsy sample of the tumor and: a) measuring levels of at least two of amphiregulin, epigen, or epiregulin in the biopsy sample, b) measuring levels of at least two of betacellulin, EGF, HB-EGF or TGFα in the biopsy sample, and c) comparing the average level measured in a) to the average level measured in b); wherein, if the average level measured in a) is greater than the average level measured in b), matuzumab should be used to treat the tumor, and if the average level measured in a) is less than or equal to the average level measured in b), matuzumab should not be used to treat the tumor. 2 . A method for determining whether or not matuzumab should be used to treat a malignant tumor, the method comprising: obtaining a biopsy sample of the tumor and: a) measuring levels of RNAs coding for at least two of amphiregulin, epigen, or epiregulin in the biopsy sample, b) measuring levels of RNAs coding for at least two of betacellulin, EGF, HB-EGF or TGFα in the biopsy sample, and c) comparing the average level measured in a) to the average level measured in b); wherein, if the average level measured in a) is greater than the average level measured in b), matuzumab should be used to treat the tumor, and if the average level measured in a) is less than or equal to the average level measured in b), matuzumab should not be used to treat the tumor. 3 . The method of claim 1 , wherein the tumor is a tumor of the skin, central nervous system, head, neck, esophagus, stomach, colon, rectum, anus, liver, pancreas, bile duct, gallbladder, lung, breast, ovary, uterus, cervix, vagina, testis, germ cells, prostate, kidney, ureter, urinary bladder, adrenal, pituitary, thyroid, bone, muscle or connective tissue. 4 . The method of claim 2 , wherein the tumor is a tumor of the skin, central nervous system, head, neck, esophagus, stomach, colon, rectum, anus, liver, pancreas, bile duct, gallbladder, lung, breast, ovary, uterus, cervix, vagina, testis, germ cells, prostate, kidney, ureter, urinary bladder, adrenal, pituitary, thyroid, bone, muscle or connective tissue.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
of the prostate · CPC title
Drugs for disorders of the respiratory system · CPC title
involving intracellular compounds · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016083800A1 cover?
- Disclosed are pharmaceutical preparations for, and methods for determining, appropriate and effective treatment with therapeutic agents comprising a single species of anti-EGFR monoclonal antibody or therapeutic agents comprising a plurality of species of such antibodies, as well as kits useful for making such determinations.
- Who is the assignee on this patent?
- Merrimack Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification G01N33/5758. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Thu Mar 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).